YTHDF3 Promoted Gastric Cancer Progression by Facilitating m

Cao Zhang, Jun Wen, Zijian Liu, Ruyi Li, Yaqin He

Abstract read

In one paragraph

Article in Analytical cellular pathology (Amsterdam), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

YTHDF3 Promoted Gastric Cancer Progression by Facilitating mAnalytical cellular pathology (Amsterdam) · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Cao ZhangDepartment of Gastrointestinal Surgery, General Hospital of Ningxia Medical University, Yinchuan, China, nxmu.edu.cn.ORCID https://orcid.org/0009-0008-6712-2279

Jun WenThe First Clinical College of Medicine, Ningxia Medical University, Yinchuan, China, nxmu.edu.cn.

Zijian LiuThe First Clinical College of Medicine, Ningxia Medical University, Yinchuan, China, nxmu.edu.cn.

Ruyi LiThe First Clinical College of Medicine, Ningxia Medical University, Yinchuan, China, nxmu.edu.cn.

Yaqin HeLaboratory of Surgery, General Hospital of Ningxia Medical University, Yinchuan, China, nxmu.edu.cn.ORCID https://orcid.org/0009-0008-8920-2819

Funding

Natural Science Foundation of Ningxia Province 2024AAC03697Study on the application of adenomatous polyposis coli gene mutations and circular RNA expression abnormalities in risk prediction and early diagnosis of gastric cancer 2021BEG03085

6 · The paper itself

Abstract

backgroundStomach adenocarcinoma (STAD) is a highly prevalent malignancy. YTH domain family protein 3 (YTHDF3), an m

methodsEpidemiologically, the GEPIA and Kaplan-Meier Plotter databases were used to examine YTHDF3 expression in STAD and to assess its association with prognosis, with poor prognosis defined by overall survival (OS). Clinical parameters were also analyzed to validate the prognostic value of YTHDF3. Experimentally, STAD patients were selected as the study objects. Immunofluorescence was used to confirm YTHDF3 expression in STAD tissues. In vitro assays examined YTHDF3/Adenomatous polyposis coli (APC) regulation of Wnt signaling.

resultsEpidemiologically, YTHDF3 elevation in STAD (p < 0.05) predicted poorer OS (hazard ratio [HR] = 1.46, 95% confidence interval [95% CI]: 1.17-1.81, p = 0.00066). High YTHDF3 expression was also significantly associated with advanced T stage (p = 0.0069), N stage (p = 0.0088), and positive distant metastasis (p = 0.0076). Experimentally, elevated YTHDF3 expression was observed in STAD tissues and cells (all p < 0.001). Silencing YTHDF3 suppresses AGS malignancy and promotes apoptosis. Conversely, YTHDF3 overexpression aggravated the malignant phenotype of STAD (all p < 0.001). Mechanistically, silencing YTHDF3 promoted APC expression (p < 0.001) in an m

conclusionYTHDF3 promoted STAD progression by regulating APC mRNA degradation.

Indexed as

AdenocarcinomaAdenomatous Polyposis Coli ProteinAdenosineDisease ProgressionRNA-Binding ProteinsRNA, MessengerRNA StabilityStomach NeoplasmsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMalePrognosisRNA MethylationWnt Signaling PathwayAdenomatous Polyposis Coli ProteinAdenosineAPC protein, humanN-methyladenosineRNA-Binding ProteinsRNA, MessengerYTHDF3 protein, humanAPCm6Astomach adenocarcinomaWnt/β-catenin signalingYTHDF3

Identifiers

PMID42742540

DOI10.1155/ancp/5045743

PMCPMC13576909

What Socratic holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.